Annual EBIT
-$78.22 M
-$39.24 M-100.67%
June 30, 2024
Summary
- As of February 7, 2025, RENB annual earnings before interest & taxes is -$78.22 million, with the most recent change of -$39.24 million (-100.67%) on June 30, 2024.
- During the last 3 years, RENB annual EBIT has fallen by -$51.75 million (-195.49%).
- RENB annual EBIT is now -261489.97% below its all-time high of -$29.90 thousand, reached on March 1, 2012.
Performance
RENB EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$43.96 M
-$29.91 M-212.79%
September 30, 2024
Summary
- As of February 7, 2025, RENB quarterly earnings before interest & taxes is -$43.96 million, with the most recent change of -$29.91 million (-212.79%) on September 30, 2024.
- Over the past year, RENB quarterly EBIT has dropped by -$34.97 million (-388.69%).
- RENB quarterly EBIT is now -3855.19% below its all-time high of $1.17 million, reached on June 1, 2019.
Performance
RENB Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$113.17 M
-$34.97 M-44.71%
September 30, 2024
Summary
- As of February 7, 2025, RENB TTM earnings before interest & taxes is -$113.17 million, with the most recent change of -$34.97 million (-44.71%) on September 30, 2024.
- Over the past year, RENB TTM EBIT has dropped by -$72.81 million (-180.39%).
Performance
RENB TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RENB EBIT Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -100.7% | -388.7% | -180.4% |
3 y3 years | -195.5% | -388.7% | -180.4% |
5 y5 years | -334.1% | -388.7% | -180.4% |
RENB EBIT Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -195.5% | +30.8% | -981.9% | +51.2% | -197.7% | at low |
5 y | 5-year | -591.4% | +30.8% | -2825.9% | +51.2% | -2417.7% | at low |
alltime | all time | <-9999.0% | +30.8% | -3855.2% | +51.2% | <-9999.0% | at low |
Renovaro Biosciences EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$43.96 M(+212.8%) | -$113.17 M(+44.7%) |
Jun 2024 | -$78.22 M(+100.7%) | -$14.05 M(-72.4%) | -$78.20 M(-10.2%) |
Mar 2024 | - | -$50.89 M(+1096.4%) | -$87.08 M(+116.4%) |
Dec 2023 | - | -$4.25 M(-52.7%) | -$40.25 M(-0.3%) |
Sep 2023 | - | -$9.00 M(-60.8%) | -$40.36 M(+3.6%) |
Jun 2023 | -$38.98 M(-65.5%) | - | - |
Jun 2023 | - | -$22.94 M(+464.5%) | -$38.97 M(-63.3%) |
Mar 2023 | - | -$4.06 M(-6.9%) | -$106.17 M(-1.9%) |
Dec 2022 | - | -$4.36 M(-42.6%) | -$108.22 M(-1.9%) |
Sep 2022 | - | -$7.60 M(-91.6%) | -$110.34 M(-2.4%) |
Jun 2022 | -$113.06 M(+327.1%) | -$90.14 M(+1376.2%) | -$113.06 M(+181.4%) |
Mar 2022 | - | -$6.11 M(-5.9%) | -$40.18 M(+5.7%) |
Dec 2021 | - | -$6.49 M(-37.1%) | -$38.01 M(+10.6%) |
Sep 2021 | - | -$10.32 M(-40.2%) | -$34.36 M(+29.8%) |
Jun 2021 | -$26.47 M(+134.0%) | -$17.27 M(+338.8%) | -$26.47 M(+100.4%) |
Mar 2021 | - | -$3.94 M(+38.5%) | -$13.21 M(+22.6%) |
Dec 2020 | - | -$2.84 M(+17.1%) | -$10.78 M(+11.6%) |
Sep 2020 | - | -$2.43 M(-39.4%) | -$9.66 M(-0.2%) |
Jun 2020 | -$11.31 M(-37.2%) | -$4.01 M(+166.6%) | -$9.67 M(+115.2%) |
Mar 2020 | - | -$1.50 M(-12.7%) | -$4.49 M(-21.5%) |
Dec 2019 | - | -$1.72 M(-29.6%) | -$5.72 M(-71.5%) |
Sep 2019 | - | -$2.44 M(-308.6%) | -$20.11 M(+3.2%) |
Jun 2019 | -$18.02 M(+186.9%) | $1.17 M(-142.9%) | -$19.48 M(-10.6%) |
Mar 2019 | - | -$2.73 M(-83.1%) | -$21.78 M(-2.3%) |
Dec 2018 | - | -$16.11 M(+788.5%) | -$22.29 M(+207.4%) |
Sep 2018 | - | -$1.81 M(+59.8%) | -$7.25 M(+27.9%) |
Jun 2018 | -$6.28 M | -$1.13 M(-65.0%) | -$5.67 M(+20.4%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2018 | - | -$3.24 M(+203.8%) | -$4.71 M(+173.3%) |
Dec 2017 | - | -$1.07 M(+364.3%) | -$1.72 M(+8.9%) |
Sep 2017 | - | -$229.60 K(+33.1%) | -$1.58 M(-27.5%) |
Jun 2017 | -$2.18 M(-0.7%) | -$172.50 K(-32.1%) | -$2.18 M(-22.9%) |
Mar 2017 | - | -$254.20 K(-72.5%) | -$2.83 M(+0.5%) |
Dec 2016 | - | -$925.50 K(+11.6%) | -$2.82 M(+6.2%) |
Sep 2016 | - | -$829.20 K(+1.1%) | -$2.65 M(+20.7%) |
Jun 2016 | -$2.20 M(-19.7%) | -$820.00 K(+240.5%) | -$2.20 M(+59.6%) |
Mar 2016 | - | -$240.80 K(-68.4%) | -$1.38 M(-42.4%) |
Dec 2015 | - | -$761.30 K(+103.8%) | -$2.39 M(-8.1%) |
Sep 2015 | - | -$373.60 K(-70.2%) | -$2.60 M(-21.4%) |
Jun 2015 | -$2.73 M(+11.0%) | - | - |
Mar 2015 | - | -$1.25 M(+29.0%) | -$3.30 M(+34.1%) |
Dec 2014 | -$2.46 M(+6541.2%) | -$970.70 K(+89.1%) | -$2.46 M(+64.1%) |
Sep 2014 | - | -$513.40 K(-9.6%) | -$1.50 M(+49.5%) |
Jun 2014 | - | -$567.70 K(+37.8%) | -$1.00 M(+128.8%) |
Mar 2014 | - | -$412.10 K(+4987.7%) | -$438.70 K(+1118.6%) |
Dec 2013 | - | -$8100.00(-49.4%) | -$36.00 K(-4.0%) |
Sep 2013 | - | -$16.00 K(+540.0%) | -$37.50 K(+31.6%) |
Jun 2013 | - | -$2500.00(-73.4%) | -$28.50 K(-23.0%) |
Mar 2013 | -$37.10 K(+24.1%) | -$9400.00(-2.1%) | -$37.00 K(+15.6%) |
Dec 2012 | - | -$9600.00(+37.1%) | -$32.00 K(-5.3%) |
Sep 2012 | - | -$7000.00(-36.4%) | -$33.80 K(-17.6%) |
Jun 2012 | - | -$11.00 K(+150.0%) | -$41.00 K(+36.7%) |
Mar 2012 | -$29.90 K(-12.8%) | -$4400.00(-61.4%) | -$30.00 K(+17.2%) |
Dec 2011 | -$34.30 K | -$11.40 K(-19.7%) | -$25.60 K(+80.3%) |
Sep 2011 | - | -$14.20 K(<-9900.0%) | -$14.20 K(<-9900.0%) |
Jun 2011 | - | $0.00 | $0.00 |
FAQ
- What is Renovaro Biosciences annual earnings before interest & taxes?
- What is the all time high annual EBIT for Renovaro Biosciences?
- What is Renovaro Biosciences annual EBIT year-on-year change?
- What is Renovaro Biosciences quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly EBIT year-on-year change?
- What is Renovaro Biosciences TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Renovaro Biosciences?
- What is Renovaro Biosciences TTM EBIT year-on-year change?
What is Renovaro Biosciences annual earnings before interest & taxes?
The current annual EBIT of RENB is -$78.22 M
What is the all time high annual EBIT for Renovaro Biosciences?
Renovaro Biosciences all-time high annual earnings before interest & taxes is -$29.90 K
What is Renovaro Biosciences annual EBIT year-on-year change?
Over the past year, RENB annual earnings before interest & taxes has changed by -$39.24 M (-100.67%)
What is Renovaro Biosciences quarterly earnings before interest & taxes?
The current quarterly EBIT of RENB is -$43.96 M
What is the all time high quarterly EBIT for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly earnings before interest & taxes is $1.17 M
What is Renovaro Biosciences quarterly EBIT year-on-year change?
Over the past year, RENB quarterly earnings before interest & taxes has changed by -$34.97 M (-388.69%)
What is Renovaro Biosciences TTM earnings before interest & taxes?
The current TTM EBIT of RENB is -$113.17 M
What is the all time high TTM EBIT for Renovaro Biosciences?
Renovaro Biosciences all-time high TTM earnings before interest & taxes is $0.00
What is Renovaro Biosciences TTM EBIT year-on-year change?
Over the past year, RENB TTM earnings before interest & taxes has changed by -$72.81 M (-180.39%)